Page last updated: 2024-09-05

deferasirox and Thrombopenia

deferasirox has been researched along with Thrombopenia in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Fu, R; Huang, L; Liu, C; Liu, Z; Tian, M1
Fujita, T; Haba, R; Nishiuchi, T; Ohnishi, H; Okutani, Y; Yoshida, K1

Other Studies

2 other study(ies) available for deferasirox and Thrombopenia

ArticleYear
Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis.
    Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2022, Volume: 70, Issue:4

    Topics: Apoptosis; Benzoates; Deferasirox; Humans; Hydrazines; Iron; Iron Chelating Agents; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia

2022
Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome.
    International journal of hematology, 2010, Volume: 91, Issue:2

    Topics: Aged; Anemia; Benzoates; Chronic Disease; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Radiography; Thrombocytopenia; Transfusion Reaction; Triazoles

2010